Keytruda Not Cost-Effective in Locally Advanced Cervical Cancer, Study Says

(MedPage Today) -- Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally advanced cervical cancer was not cost-effective in an economic evaluation study.
Adding concurrent...